X T L Biopharmaceuticals reported $76K in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Bioline Rx USD 2.5M 5.41M Mar/2026
Teva Pharmaceutical Industries USD 3.74B 185M Mar/2026
X T L Biopharmaceuticals USD 76K 295K Dec/2025